BY THE DIGITAL HEALTH LEADERS FOR THE DIGITAL HEALTH COMMUNITY
BY THE DIGITAL HEALTH LEADERS 
AstraZeneca's COPD Treatment Gains Approval from CDSCO December 20, 2023 COPD, the second leading cause of death in India, constitutes over 50% of chronic respiratory diseases and is the third leading cause of death globally.
AstraZeneca Buys Respiratory Vaccine Developer Icosavax in $1.1 Bn Deal December 14, 2023 Icosavax is developing a combination vaccine candidate targeting RSV and human metapneumovirus (hMPV). RSV is a leading cause of pneumonia in toddlers and the elderly, while hMPV causes very similar respiratory tract infections.
AstraZeneca India Partners with Roche Diagnostics to Improve Diagnostic Testing December 13, 2023 The initiative focuses on streamlining HER2 diagnostics with newer advancements in cancer treatment. Further, the partnership will offer comprehensive training initiatives for pathologists and medical oncologists.
AstraZeneca & Absci Join Hands in a $247 Mn Cancer Drug Deal December 4, 2023 The partnership will leverage Absci's Al technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca. However, the companies didn’t specify the type of cancer they plan to target.
AstraZeneca Inks Investment Agreement with Cellectis to Accelerate Next Generation Therapeutics November 2, 2023 The partnership aims to combine cutting-edge gene editing and cell therapy research with our advanced manufacturing technology to deliver life-saving therapies for patients with unmet medical needs.
Karnataka Govt Signs MoU with AstraZeneca to Deploy AI-Based Lung Cancer Screening Technology October 13, 2023 To be implemented in 19 district hospitals in Karnataka, this AI-driven chest X-ray system facilitates early detection of lung nodules, enhancing the healthcare system's ability to diagnose cancer at its initial stages.
AstraZeneca India gets CDSCO Marketing Approval for Palivizumab, a Preventive Therapy for RSV October 4, 2023 AstraZeneca Pharma India, a leading biopharmaceutical company has received marketing approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute €˜Palivizumab injection 100 mg/ml (r-DNA origin) in India.
AstraZeneca's Rare Disease Unit Buys Pfizer Portfolio September 20, 2023 The global pharma giant AstraZeneca's rare disease unit Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.
British-Swedish Pharma Giant AstraZeneca's Alexion Partners with USA's Verge Genomics in a $840 Mn+ Deal September 13, 2023 British-Swedish pharmaceutical major, AstraZeneca, has formed a partnership between its rare disease unit, Alexion, with American biotechnology firm Verge Genomics. The partnership deal is reported to be valued at over $840 million
